Insertion-Site Necrosis of the Single-Rod Subdermal Contraceptive Implant: Case Reports

Faranna MD*, Huespe M and Analia P

*D F Santojanni Public Hospital, Pilar 950 CABA, Buenos Aires, Argentina.

Received August 08, 2021; Revised August 31, 2021; Accepted September 02, 2021

ABSTRACT

Implant-site necrosis is a rare complication. Local pain was the main symptom, appearing within 35 days of placement. Ambulatory multidisciplinary treatment was undertaken. Local debridement and implant removal was performed in 4 out of five patients. Time to complete healing varied from 45 days -12 months, depending on the wound.

Keywords: Contraceptive implant, Insertion-Site necrosis, Complication, Severe side effects

INTRODUCTION

The single-rod subdermal contraceptive implant containing etonogestrel (Implanon® MSD Merck Sharp & Dohme; Cazadores de Coquimbo 2841, Buenos Aires, Argentina), approved by the Food and Drug Administration in 2006, offers 3-year-long, reversible contraception [1], is over 99% effective, with a Pearl rate between 0.00-0.14 [2], and discontinuity rate of 16% per year of use [3]. Implant insertion-site complications are rare, with an incidence ranging from 0.3%-3.6% [4,5]. Implant insertion-site necrosis is a rare adverse effect, with scarce literature published worldwide. It comprises variable levels of tissue damage, ranging from local whitening, edema and reddening, to subcutaneous cellular tissue damage. The physiopathology is not entirely clear but could be generated by barium sulphate allergy, insertion-site infection, or vascular damage due to embolism, vasospasm, or inflammation secondary to a local cytotoxic drug [5-11].

OBJECTIVE

To present clinical manifestations and treatment of 5 cases of subdermal contraceptive implant insertion-site necrosis.

MATERIALS AND METHODS

Medical records’ information of women in whom Implanon® was placed were reviewed in search of insertion-site complications occurring between February 2015 and September 2019. Written consent was obtained from all patients on whom the report is based. Sexual and Reproductive Health National Program.

CLINICAL CASES

Of the 995 implanted patients, five presented insertion-site necrosis (0.5%). It represented 16% of implant-related early discontinuation causes. The events were reported to the manufacturer, and to the Sexual and Reproductive Health National Program in Argentina, that reports to the ANMAT. Clinical presentation and treatment details are summarized in Table 1. Symptom onset was within 35 days of implant placement, with patients referring pain as the main symptom. An ambulatory multidisciplinary patient treatment was undertaken, in cooperation with the Plastic Surgery and Infectology Departments. None showed compromise beyond the subcutaneous cellular tissue. No abscesses were found and none progressed towards gangrene or sepsis. Local debridement was performed in four patients, one of them requiring necrotic tissue removal in an operating room, under locoregional plexus nerve block. In these 4 patients, the implant was also removed. All but one received antibiotic treatment, even in the absence of pathogens in tissue cultures. Tissue biopsy indicated a severe inflammatory process, with epidermal ulcer and areas of necrosis. Time until complete healing varied from 45 days-12 months, depending on the extent of the wound.

Corresponding author: Faranna MD, Obstetrics and Neonatology Department. D. F. Santojanni Public Hospital. Pilar 950 CABA, Buenos Aires Argentina, Tel: 5491153268609, E-mail: faranna_maria25@yahoo.com.ar


Copyright: ©2022 Faranna MD, Huespe M & Analia P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Table 1. Case series summary.

<table>
<thead>
<tr>
<th>Case No</th>
<th>Age (years)</th>
<th>Prior medical history</th>
<th>Time to symptom onset (days)</th>
<th>Symptoms</th>
<th>Clinical exam</th>
<th>Treatment</th>
<th>Wound culture</th>
<th>Antibiotic treatment</th>
<th>Implant removed</th>
<th>Time to complete healing</th>
<th>Contraceptive method chosen after complication</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>21</td>
<td>No</td>
<td>3</td>
<td>Local pain</td>
<td>Wound with central necrosis (Figure 1)</td>
<td>Debridement (Figure. 2) + wound dressing with Platsul®</td>
<td>No</td>
<td>Oral cephalexin</td>
<td>Yes</td>
<td>12 months (Figure. 3)</td>
<td>Monthly combined intramuscular contraceptive</td>
</tr>
<tr>
<td>2</td>
<td>24</td>
<td>No</td>
<td>7</td>
<td>Local pain + burning sensation</td>
<td>Insertion-site ulcer (Figure. 4)</td>
<td>Debridement under general anestesia + wound dressing.</td>
<td>Negative</td>
<td>Oral cephalexin</td>
<td>Yes</td>
<td>12 months</td>
<td>Monthly combined intramuscular contraceptive</td>
</tr>
<tr>
<td>3</td>
<td>28</td>
<td>No</td>
<td>10</td>
<td>Local pain + erythema</td>
<td>Implant exposure in necrotic wound (Figure. 5)</td>
<td>Debridement (Figure. 6) + wound dressing with biofilm</td>
<td>Klebsiella Oxytoca</td>
<td>Oral amoxicillin + clavulanic acid</td>
<td>Yes</td>
<td>6 months</td>
<td>Condom</td>
</tr>
<tr>
<td>4</td>
<td>25</td>
<td>Obesity</td>
<td>2</td>
<td>Local pain + burning sensation</td>
<td>Unroofed blistered lesion (Figure. 7)</td>
<td>Wound dressing with biofilm + Platsul®</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>5 months (Figure. 8)</td>
<td>Implanon®</td>
</tr>
<tr>
<td>5</td>
<td>17</td>
<td>No</td>
<td>35</td>
<td>Local pain + erythema</td>
<td>Implant exposure in necrotic wound</td>
<td>Debridement + wound dressing.</td>
<td>Staphylococcus aureus</td>
<td>Oral cephalexin</td>
<td>Yes</td>
<td>45 days (Figure. 9)</td>
<td>Oral contraceptive</td>
</tr>
</tbody>
</table>

Figure 1. Case 1. 6cm, third-degree burn-like wound with central necrosis.

Figure 2. Case 1. Immediate result after skin and subcutaneous cellular tissue debridement.
Figure 3. Case 1. Consolidated hypopigmented atrophic scar, with slightly hyperpigmented edges.

Figure 4. Case 2. Insertion-site 7x4 cm ulcer with a peripheral inflammatory halo.

Figure 5. Case 3. 7x5cm wound with central necrosis and peripheral indurated edges.

Figure 6. Case 3. After local skin and subcutaneous cellular tissue debridement.

Figure 7. Case 4. Superficial 8x7cm wound, affecting only the dermis, with granulation tissue covering over 90% of the wound. Absence of subcutaneous cellular tissue involvement.

Figure 8. Case 4. Complete reepithelization after 5 months, with residual local hyperpigmentation. The patient referred sporadic localized itching and burning sensation over the scar.
Figure 9. Case 5: Keloid scar after 45 days.

COMMENT

The information presented in this report does not aim to question the safety of Implanon®, but to describe a potential implant-related severe side effect. A published U.S. experience did not report cases of skin necrosis following these insertions [12]. Those that occurred in our cohort were not associated with a particular inserting physician or local anesthesia used. The implants in this series were placed by trained physicians, with a standardized technique. Insertion-site erythema or pain should alarm about the development of local complications. In the presence of necrotic tissue, wound debridement is the treatment of choice, and in most cases, the implant should be removed. Early diagnosis and multidisciplinary treatment are essential to avoid major life-threatening complications, severe aesthetic and/or functional damages.

ACKNOWLEDGMENTS

To the chiefs and staff of the Gynecology and Obstetrics Departments to the Staff of the Sexual and Reproductive Health Program, who provide us the supplies to our work.

To Dr. C. Chwat that assisted in the drafting of this study.

CONCLUSION

The subdermal implant is an excellent tool to prevent and reduce teenage pregnancy. Although the incidence of necrosis after its placement is low, we consider important to know this side effect, its form of presentation in order to make an acute diagnosis and treatment.

REFERENCES